Benzene-Ring P2X4 Antagonists With Selective Low-Toxicity Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current P2X4 antagonists have monotonous structures and lack selectivity, toxicity, and metabolic stability, making them inadequate for treating chronic cough and other respiratory conditions.
Innovation Solution
A compound containing a benzene ring with specific functional groups and heteroatoms, represented by formula I, exhibits high P2X4 antagonistic activity, good selectivity, and low toxicity, offering potential therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing P2X4 antagonists are used, then P2X4 receptor inhibition is achieved, but the compounds suffer from monotonous structure, poor selectivity, high toxicity and bad metabolic stability
Solution Approach 1:
The patent applies parameter changes by systematically varying key structural parameters of the P2X4 antagonist molecules. Specifically, it modifies the benzene ring substitution patterns (introducing different groups at positions 2, 4, and 6), changes the heterocyclic ring types (pyridine, pyrimidine, triazine variants), and adjusts linker characteristics (ethylene diamine, propylene diamine with different configurations). These parameter variations generate a diverse library of compounds that maintain P2X4 inhibitory activity while improving selectivity and reducing toxicity compared to existing antagonists
2Reliability
If existing P2X4 antagonists are used, then P2X4 receptor inhibition is achieved, but the compounds lack selectivity
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions on the benzene ring structure. The substitution pattern (2,4,6-trisubstituted benzene) creates distinct local chemical environments that enhance binding selectivity to P2X4 receptor while maintaining the core inhibitory activity. This localized structural optimization allows the compounds to differentiate between P2X4 and other purinergic receptors
3Reliability
If existing P2X4 antagonists are used, then P2X4 receptor inhibition is achieved, but the compounds show monotonous structure
Solution Approach 1:
The patent applies composite materials by combining multiple structural components into a unified P2X4 antagonist framework. The compounds integrate a 2,4,6-trisubstituted benzene core with diverse heterocyclic rings (pyridine, pyrimidine, triazine and their substituted variants) connected through flexible diamine linkers. This composite structure combines the benefits of aromatic stability, heterocyclic binding affinity, and linker flexibility, creating structurally diverse compounds with improved pharmacological properties
Data Source
AI summary
Provided are a compound containing a benzene ring as shown in formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic compound thereof, a crystal form thereof, a nitrogen oxide thereof, and a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof. The compound has high P2X4 antagonistic activity, good selectivity, low toxicity and good metabolic stability.